Phase 1 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a type of blood cancer called acute myeloid leukaemia (AML) that has come back or stopped responding to treatment, and who are not eligible for standard treatment options.
- People whose AML has returned after a first period of remission and for whom a second round of standard induction chemotherapy is not considered appropriate by their treating doctor.
- People whose AML has returned after a second period of remission.
- People whose AML did not respond to initial chemotherapy treatment.
- People who have been diagnosed with a blood disorder called myelodysplastic syndrome (MDS) that is classified as intermediate, high-risk, or very high-risk, or that has a specific gene mutation called TP53, and whose disease did not respond to, lost response to, or could not tolerate at least 4 cycles of a standard treatment (azacitidine or decitabine).
- People whose disease can be measured and tracked using standard medical scoring systems for AML or MDS.
- People whose blast cell count (a type of abnormal cell) in the blood is below 15,000 per litre.
- People whose liver and kidney functions are within acceptable ranges as determined by standard blood tests.
- People whose heart is pumping at least 40% of its capacity, as confirmed by a heart scan.
- People whose lung function meets specific breathing test criteria (confirm with trial site).
Who may not be able to join:
- People who have, or have previously had, cancer involvement in the brain or spinal cord.
- People who have recently received any cancer treatment (standard or experimental) intended to treat their disease.
- People who have certain positive results on blood infection or immunity screening tests taken at the start of the trial.
- People who have received any experimental treatment within the 3 weeks before the planned first treatment infusion in this trial.
- People with serious medical conditions that are not under control.
- People with significant blood clotting disorders, or who are currently taking blood-thinning medications such as warfarin, heparin, or direct oral anticoagulants.
- People who currently have an active infection.
- People with a documented history of certain lung conditions, including pulmonary fibrosis, organising pneumonia, drug-related lung inflammation, or a current flare-up of chronic obstructive pulmonary disease (COPD).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 003210394100
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Occurrence of Dose Limiting Toxicities as defined per protocol in order to define the final recommended dose.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.